CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* 1.Age ≥ 18 years old (inclusive), regardless of gender.
* 2.Positive expression of CD19 on peripheral blood B cells confirmed by flow cytometry.
* 3.Functional requirements for major organs are as follows:

  1. Bone marrow function must meet: A. Neutrophil count ≥ 0.5×10 \^ 9/L (no colony-stimulating factor treatment within 2 weeks before examination); B. Hemoglobin ≥ 60g/L; C. Platelets ≥ 30 × 10 \^ 9/L.
  2. Liver function: Alanine aminotransferase (ALT) ≤ 3×ULN (excluding ALT elevation due to inflammatory myopathy), aspartate aminotransferase (AST)≤3×Upper limit of normal (ULN) (excluding AST elevation due to inflammatory myopathy), TBIL≤1.5×ULN (or ≤ 3.0×ULN for subjects with Gilbert syndrome);
  3. Renal function: creatinine clearance rate (CrCl) ≥ 30ml/minute (calculated by Cockcroft/Gault formula, acute CrCl decrease due to the target disease is excluded; LN is exluded);
* 4.ECOG score 0-1.
* 5.Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.
* 6.Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.
* 7.Subjects with relapsed or refractory autoimmune diseases, Including relapsed or refractory Autoimmune Hemolytic Anemia, relapsed or refractory Systemic Lupus Erythematosus, relapsed or refractory or Progressive Systemic Sclerosis, relapsed or refractory or Progressive Inflammatory Myopathy, relapsed or refractory ANCA-Associated Vasculitis, relapsed or refractory Immunoglobulin-G4 related disease and relapsed or refractory Myasthenia Gravis.

Exclusion Criteria:

* 1.Subjects with a history of severe drug allergies or allergic constitutions;
* 2\. Presence or suspicion of uncontrolled or treatment-required fungal, bacterial, viral, or other infections;
* 3\. Subjects with insufficient cardiac function;
* 4\. Subjects with congenital immunoglobulin deficiencies;
* 5\. Subjects with a history of malignant tumors within the past five years, except for the following conditions: non-melanoma skin cancer, stage I tumors with a low recurrence probability after complete resection, clinically localized prostate cancer after treatment, cervical carcinoma in situ confirmed by biopsy or squamous intraepithelial lesion shown by smear, and stable papillary thyroid carcinoma or follicular thyroid carcinoma.
* 6\. Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \>ULN; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing;
* 7\. Subjects with mental illness and severe cognitive dysfunction;
* 8\. Pregnant women or women planning to conceive;
* 9.Subjects whom the investigator believes have other reasons that make them unsuitable for inclusion in this study.

主要终点：The number and severity of dose-limiting toxicity (DLT) events · DLT will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, and the ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. · Within 28 Days After UCAR T-cell Infusion；The total number, incidence, and severity of AEs · Up to 90 days After UCAR T-cell Infusion
次要终点：AIHA：Rates of CR, CRi, PR, ORR；SLE：SLE Response Index 4 (SRI-4)；SLE: Change in the Systemic Lupus Erythematosus Disease Activity Index(SLEDAI) from baseline；SSc：Change in the modified Rodnan Skin Score (mRSS) from baseline；IIM：The ACR-EULAR Myositis Response Criteria [Total Improvement Score (TIS)]；AAV: Change in disease activity as measured by Birmingham Vasculitis Activity Score (BVAS)；IgG4-RD:IgG4-Related Disease Responder Index (IgG4-RD RI)；MG:Changes of Myasthenia Gravis Activities of Daily Living (MG-ADL) Score

• UCAR T-cell group · EXPERIMENTAL · A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.